Download Sample
Schedule a Meeting
NA : +1 804 441 9344
sales@towardshealthcare.com
August 2025
The global neuroscience clinical trials market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the hundreds of millions over the forecast years from 2025 to 2034. This surge is attributed to evolving consumer preferences and technological advancements reshaping the industry.
The neuroscience clinical trials market is growing steadily, driven by the rising burden of neurological disorders and the urgent need for effective therapies. Advances in neuroimaging, biomarkers, and precision medicine are enabling more targeted and efficient trials. Pharmaceutical and biotech companies are heavily investing in R&D for conditions like Alzheimers, Parkinsons, and multiple sclerosis. Additionally, supportive gove ment initiatives, increasing collaborations, and technological integration in trial design are accelerating progress, making neuroscience one of the most dynamic clinical research areas.
The Neuroscience Clinical Trials Market covers all sponsored clinical research (Phase I–IV) investigating interventions for nervous system disorders, including neurological (Alzheimers, Parkinsons, epilepsy, MS, stroke, ALS, migraine, neuropathic pain) and neuropsychiatric conditions (major depressive disorder, schizophrenia, bipolar disorder, anxiety, PTSD). It spans pharmacologic therapies (small molecules, biologics), advanced modalities (gene & cell therapies, oligonucleotides), neuromodulation devices (DBS, TMS, RNS), digital therapeutics/biomarkers, and combination approaches. Market growth is driven by an ageing population, unmet need in neurodegeneration and psychiatric care, advances in biomarkers and imaging, increasing use of precision / gene-based approaches, and higher investment in CNS R&D despite historically high attrition.
The neuroscience clinical trials market is expanding as lifestyle-related neurological issues, including stress-induced disorders and cognitive decline, become more common. Growing interest in novel therapeutic approaches such as neuromodulation, stem cell therapy, and RNA-based drugs is also fueling demand. Additionally, the rise of decentralized and virtual trial models is improving patient recruitment and retention, accelerating market growth.
For Instance,
Novel Therapeutic Development : Innovations like gene therapy, neuromodulation, and RNA-based drugs are expanding treatment options, fueling research.
Collaborations and Partnerships : Academic institutions, hospitals, and industry partnerships streamline trial operations and access to patient populations.
AI can significantly impact the market by improving patient recruitment, predicting disease progression, and optimizing trial design. Machine lea ing algorithms can analyze large datasets from imaging, genomics, and electronic health records to identify suitable participants and detect early neurological changes. AI-driven analytics enhance monitoring of treatment responses and adverse events, reducing trial duration and costs. Additionally, integrating AI with digital biomarkers and wearable devices enables real-time data collection, supporting more precise and efficient neuroscience clinical trials.
Rising Prevalence of Neurological Disorders
The increasing incidence of neurological disorders worldwide is driving the neuroscience clinical trials market as healthcare systems seek better preventive and therapeutic solutions. Growing awareness among patients and clinicians about early diagnosis and intervention is boosting participation in trials. Additionally, the economic and societal burden on cognitive and private organizations to support more research initiatives creates a higher demand for clinical studies focused on innovative neuroscience treatments.
High Cost of Clinical Trials
The high cost of neuroscience clinical trials restrains the market because developing therapies for neurological disorders often requires multi-site studies, specialized personnel, and cutting-edge laboratory infrastructure. Expenses for patient screening, long-term follow-ups, and handling adverse events further add to the financial burden. Smaller biotech companies and research institutions may struggle to fund such trials, limiting innovation and slowing the initiation of new studies. The financial barrier constrains market growth despite rising demand for neurological treatments.
For Instance,
Personalized and Precision Medicine
Personalized and precision medicine offers a key opportunity in neuroscience clinical trials by enabling more efficient identification of patients likely to respond to specific therapies. By leveraging genomics data, biomarkers, and digital health insights, trials can focus on targeted populations, reducing costs and trial durations. This approach also supports the development of innovative treatments for complex neurological disorders, such as rare genetic diseases and treatment-resistant conditions, creating a growing demand for customized clinical trial design and advanced monitoring technologies.
For Instance,
The psychiatric disorders segment led the neuroscience clinical trials market as these conditions increasingly affect working-age populations, creating a pressing need for innovative treatments. Rising adoption of digital health tools, wearable monitoring, and telemedicine supports more efficient trials in depression, anxiety, and schizophrenia. Moreover, expanding gove ment and private funding for mental health research, coupled with growing interest in novel therapies like neuromodulation and biologics, has accelerated clinical studies, reinforcing this segments strong market position.
The neurodegenerative diseases segment is projected to grow rapidly as pharmaceutical and biotech companies intensify efforts to address unmet needs in conditions like Alzheimers and Parkinsons. Breakthrough therapies, including gene and stem cell treatments, are increasing the number of clinical trials. Furthermore, heightened public awareness, early diagnostics programs, and the use of digital tools for monitoring disease progression are enabling more efficient and targeted studies, making this therapy area a key driver of market expansion during the forecast period.
The small molecules segment dominated in 2024 as these therapies offer high stability, longer shelf life, and simpler formulation compared to complex biologics. Their versatility allows targeting multiple pathways in neurological and psychiatric disorders, making them suitable for a wide range of clinical trials. Additionally, established intellectual property frameworks and easier global distribution contribute to their market preference, enabling faster patient access and broader adoption, which helped the small molecules segment achieve the largest revenue share within therapeutic modalities.
The gene & oligonucleotide therapies segment is expected to grow rapidly due to rising demand for personalized treatment that modifies disease pathways at the molecular level. Innovations in viral and non-viral delivery systems, along with enhanced targeting accuracy, are making these therapies more feasible for neurological disorders. Additionally, collaborations between biotech firms and academic institutions are expanding clinical trial pipelines, while regulatory incentives for breakthrough therapies are encouraging faster development, driving this segments strong CAGR in neuroscience clinical trials.
The phase I/I-II segment led the neuroscience clinical trials market in 2024 because these stages allow rapid testing of innovative therapies for neurological and psychiatric disorders before large-scale trials. Early-phase studies are crucial for optimising dosing, delivery methods, and identifying potential side effects, attracting significant investment from biotech and pharmaceutical companies. He surge in novel modalities, such as oligonucleotide and gene therapies, has further increased the number of early-stage trials, securing this segments top market share in neuroscience clinical research.
The phase III/pivotal segment is projected to grow rapidly as companies focus on securing regulatory approvals for promising neuroscience therapies. Late-stage trials are increasingly global, enrolling larger and more diverse patient populations to generate robust efficacy and safety data. Rising collaboration between pharma, biotech, and research organizations, along with advances in trial monitoring and digital endpoints, is enabling faster and more efficient pivotal studies. These factors collectively drive the accelerated growth of the phase III segment.
North America led the market share 45% in 2024, owing to early adoption of innovative trial designs, digital health technologies, and precision medicine approaches. Strong collaboration between academic institutions, hospitals, and the pharmaceutical industry facilitated efficient patient recruitment and study execution. Additionally, the regions focus on rare neurological disorders and growing awareness of mental health challenges drove more clinical research, establishing North America as the top contributor to market revenue in neuroscience clinical trials.
The U.S. market is expanding due to the increasing prevalence of neurological and psychiatric disorders, including Alzheimers, Parkinsons, and depression. Strong R&D investments by pharmaceutical and biotechnology companies, coupled with advanced clinical infrastructure, support rapid trial execution. Additionally, regulatory incentives for innovative therapies, adoption of digital health tools, and collaborations between academic institutions and industry are enhancing trial efficiency. Growing demand for personalized medicine and targeted treatments further fuels the expansion of neuroscience clinical trials in the U.S.
The market in Canada is growing as the country increasingly attracts global clinical studies due to its streamlined regulatory processes and strong patient access networks. Rising awareness of neurological disorders and increased funding for mental health research are encouraging more trials. Furthermore, Canadian research institutions are adopting advanced technologies like neuroimaging and digital biomarkers, enabling precise monitoring and faster data collection, which is accelerating the growth of neuroscience clinical trials in the region.
Asia-Pacific is anticipated to record the fastest CAGR as the region experiences a surge in contract research organizations (CROs) and clinical trial centers, improving trial accessibility and efficiency. Increasing awareness of neurological health, coupled with rising middle-class populations seeking advanced treatments, fuels demand for innovative therapies. Additionally, gove ments are offering incentives to attract inte ational trials, and growing adoption of decentralized and digital trial models enables broader patient participation, collectively accelerating the growth of neuroscience clinical trials in the region.
Regulatory approval for neuroscience clinical trials requires compliance with the guidelines of the respective national authorities, such as the FDA in the United States and the CDSCO in India. Trials must also follow the Good Clinical Practice (GCP) standards set by the Inte ational Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), ensuring safety, quality, and ethical conduct throughout the study.
Patient support and services in neuroscience clinical trials encompass a comprehensive strategy, including educating and advocating for participants, providing on-site assistance from clinical staff, offering financial aid, utilizing digital platforms, and fostering community engagement. These measures aim to enhance patient access, ensure smooth participation, and create a positive experience throughout the trial process.
Packaging and serialization in neuroscience clinical trials maintain product quality and safeguard patients by giving each drug package a unique identifier. This system enables tracking throughout the supply chain, ensuring authenticity and preventing counterfeit products from reaching participants.
In May 2025, Aspen Neuroscience shared six-month results from the ASPIRO Phase 1/2a trial of ANPD001, a personalized dopaminergic cell therapy for moderate to advanced Parkinsons disease. The first three patients showed safety, tolerability, and early improvements. Dr. Avram Fraint noted that precision delivery of DANPCs is safe and well-tolerated. Edward Wirth III highlighted clinician- and patient-reported benefits and that ANPD001 requires no immunosuppression. CEO Damien McDevitt said the findings are promising for both Parkinsons patients and the autologous cell therapy field.
By Indication / Therapeutic Area
By Therapeutic Modality
By Clinical Phase
By Region
August 2025
August 2025
August 2025
August 2025